BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gordon C, Amissah-arthur M, Gayed M, Brown S, Bruce IN, D’cruz D, Empson B, Griffiths B, Jayne D, Khamashta M, Lightstone L, Norton P, Norton Y, Schreiber K, Isenberg D; for the British Society for Rheumatology Standards, Audit and Guidelines Working Group. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology 2018;57:e1-e45. [DOI: 10.1093/rheumatology/kex286] [Cited by in Crossref: 117] [Cited by in F6Publishing: 92] [Article Influence: 23.4] [Reference Citation Analysis]
Number Citing Articles
1 Harcken C, Scholl P, Nabozny G, Thomson D, Bianchi D. Clinical profile of the functionally selective glucocorticoid receptor agonist BI 653048 in healthy male subjects. Expert Opin Investig Drugs 2019;28:489-96. [PMID: 30908082 DOI: 10.1080/13543784.2019.1599859] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Sloan M, Bosley M, Blane M, Holloway L, Barrere C, D'Cruz D, Walia C, Naughton F, Howard P, Sutton S, Gordon C. 'But you don't look sick': a qualitative analysis of the LUPUS UK online forum. Rheumatol Int 2021;41:721-32. [PMID: 33104839 DOI: 10.1007/s00296-020-04726-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Miyazaki C, Sruamsiri R, Mahlich J, Jung W. Treatment patterns and medical cost of systemic lupus erythematosus patients in Japan: a retrospective claims database study. J Med Econ 2020;23:786-99. [PMID: 32149541 DOI: 10.1080/13696998.2020.1740236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Keeling SO, Alabdurubalnabi Z, Avina-Zubieta A, Barr S, Bergeron L, Bernatsky S, Bourre-Tessier J, Clarke A, Baril-Dionne A, Dutz J, Ensworth S, Fifi-Mah A, Fortin PR, Gladman DD, Haaland D, Hanly JG, Hiraki LT, Hussein S, Legault K, Levy D, Lim L, Matsos M, McDonald EG, Medina-Rosas J, Pardo Pardi J, Peschken C, Pineau C, Pope J, Rader T, Reynolds J, Silverman E, Tselios K, Suitner M, Urowitz M, Touma Z, Vinet E, Santesso N. Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus. J Rheumatol 2018;45:1426-39. [PMID: 30173152 DOI: 10.3899/jrheum.171459] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
5 Langham J, Barut V, Samnaliev M, Langham S, Weir S, Wang X, Desta B, Hammond E. Disease severity, flares and treatment patterns in adults with systemic lupus erythematosus in the UK: a real-world observational retrospective cohort analysis. Rheumatol Adv Pract 2021;5:rkab061. [PMID: 34557623 DOI: 10.1093/rap/rkab061] [Reference Citation Analysis]
6 Hennessey A, Lukawska J, Cambridge G, Isenberg D, Leandro M. Adverse infusion reactions to rituximab in systemic lupus erythematosus: a retrospective analysis. BMC Rheumatol 2019;3:32. [PMID: 31485560 DOI: 10.1186/s41927-019-0082-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
7 Sloan M, Harwood R, Sutton S, D'Cruz D, Howard P, Wincup C, Brimicombe J, Gordon C. Medically explained symptoms: a mixed methods study of diagnostic, symptom and support experiences of patients with lupus and related systemic autoimmune diseases. Rheumatol Adv Pract 2020;4:rkaa006. [PMID: 32373774 DOI: 10.1093/rap/rkaa006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
8 Chanprapaph K, Ploydaeng M, Pakornphadungsit K, Mekwilaiphan T, Vachiramon V, Kanokrungsee S. The behavior, attitude, and knowledge towards photoprotection in patients with cutaneous/systemic lupus erythematosus: a comparative study with 526 patients and healthy controls. Photochem Photobiol Sci 2020;19:1201-10. [PMID: 32935699 DOI: 10.1039/d0pp00073f] [Reference Citation Analysis]
9 Sloan M, Gordon C, Harwood R, Lever E, Wincup C, Bosley M, Brimicombe J, Pilling M, Sutton S, Holloway L, D'Cruz D. The impact of the COVID-19 pandemic on the medical care and health-care behaviour of patients with lupus and other systemic autoimmune diseases: a mixed methods longitudinal study. Rheumatol Adv Pract 2021;5:rkaa072. [PMID: 33604501 DOI: 10.1093/rap/rkaa072] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
10 Gergianaki I, Bertsias G. Systemic Lupus Erythematosus in Primary Care: An Update and Practical Messages for the General Practitioner. Front Med (Lausanne) 2018;5:161. [PMID: 29896474 DOI: 10.3389/fmed.2018.00161] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 5.8] [Reference Citation Analysis]
11 Redmond C, Pamuk O, Hasni SA. Lupus Cohorts. Rheum Dis Clin North Am 2021;47:457-79. [PMID: 34215374 DOI: 10.1016/j.rdc.2021.04.009] [Reference Citation Analysis]
12 Khodashahi R, Naderi H, Bojdy A, Khodashahi M. Effectiveness of Antiviral and Immunomodulatory Agents in the Treatment of COVID-19: A Systematic Review. CRMR 2021;16:165-83. [DOI: 10.2174/1573398x16999201202121247] [Reference Citation Analysis]
13 Dörner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet 2019;393:2344-58. [PMID: 31180031 DOI: 10.1016/S0140-6736(19)30546-X] [Cited by in Crossref: 115] [Cited by in F6Publishing: 62] [Article Influence: 38.3] [Reference Citation Analysis]
14 Yavne Y, Edel Y, Berman J, Eviatar T, Shepshelovich D. Quality Evaluation of the Underlying Evidence in the Updated Treatment Recommendations for Systemic Lupus Erythematosus. Rheumatology (Oxford) 2021:keab306. [PMID: 33764408 DOI: 10.1093/rheumatology/keab306] [Reference Citation Analysis]
15 Scolnik M, Scaglioni V, Pons-Estel GJ, Soriano ER. Management of non-renal non-neurologic persistent lupus activity in real world patients from Argentina. Lupus 2019;28:1167-73. [PMID: 31299882 DOI: 10.1177/0961203319861687] [Reference Citation Analysis]
16 Chen YJ, Chang JC, Lai EL, Liao TL, Chen HH, Hung WT, Hsieh TY, Huang WN, Chen YH, Lin CH, Chen YM. Maternal and perinatal outcomes of pregnancies in systemic lupus erythematosus: A nationwide population-based study. Semin Arthritis Rheum 2020;50:451-7. [PMID: 32115237 DOI: 10.1016/j.semarthrit.2020.01.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
17 Leone P, Cicco S, Prete M, Solimando AG, Susca N, Crudele L, Buonavoglia A, Colonna P, Dammacco F, Vacca A, Racanelli V. Early echocardiographic detection of left ventricular diastolic dysfunction in patients with systemic lupus erythematosus asymptomatic for cardiovascular disease. Clin Exp Med 2020;20:11-9. [DOI: 10.1007/s10238-019-00600-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
18 Porta S, Danza A, Arias Saavedra M, Carlomagno A, Goizueta MC, Vivero F, Ruiz-Irastorza G. Glucocorticoids in Systemic Lupus Erythematosus. Ten Questions and Some Issues. J Clin Med 2020;9:E2709. [PMID: 32839376 DOI: 10.3390/jcm9092709] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
19 Ramanujam M, Steffgen J, Visvanathan S, Mohan C, Fine JS, Putterman C. Phoenix from the flames: Rediscovering the role of the CD40-CD40L pathway in systemic lupus erythematosus and lupus nephritis. Autoimmun Rev 2020;19:102668. [PMID: 32942031 DOI: 10.1016/j.autrev.2020.102668] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
20 Zeng X, Zheng L, Rui H, Kang R, Chen J, Chen H, Liu J. Risk factors for the flare of systemic lupus erythematosus and its influence on prognosis: a single-center retrospective analysis. Adv Rheumatol 2021;61:43. [PMID: 34215349 DOI: 10.1186/s42358-021-00202-7] [Reference Citation Analysis]
21 Vicente-Rabaneda EF, Serra López-Matencio JM, Ancochea J, Blanco R, González-Gay MÁ, Castañeda S. Efficacy and safety of biological drugs in interstitial lung disease associated with connective tissue diseases. Expert Opin Drug Saf 2021;:1-23. [PMID: 34433372 DOI: 10.1080/14740338.2021.1973428] [Reference Citation Analysis]
22 Furie RA, Mitrane M, Zhao E, Becker PM. Repository corticotropin injection in patients with persistently active SLE requiring corticosteroids: post hoc analysis of results from a two-part, 52-week pilot study. Lupus Sci Med 2017;4:e000240. [PMID: 29344387 DOI: 10.1136/lupus-2017-000240] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
23 Jesus D, Matos A, Henriques C, Zen M, Doria A, Inês LS. Response to: 'SLE-DAS: ready for routine use' by Mathew et al. Ann Rheum Dis 2020;79:e117. [PMID: 31201172 DOI: 10.1136/annrheumdis-2019-215794] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Yu Y, Li J, Wang S, Gao Y, Shen H, Lu L. Effect of Candida albicans bronchial colonization on hospital-acquired bacterial pneumonia in patients with systemic lupus erythematosus. Ann Transl Med 2019;7:673. [PMID: 31930074 DOI: 10.21037/atm.2019.10.44] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
25 Gordon C, Amissah-Arthur MB, Gayed M, Brown S, Bruce IN, D'Cruz D, Empson B, Griffiths B, Jayne D, Khamashta M, Lightstone L, Norton P, Norton Y, Schreiber K, Isenberg D; British Society for Rheumatology Standards, Audit and Guidelines Working Group. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: Executive Summary. Rheumatology (Oxford) 2018;57:14-8. [PMID: 29029296 DOI: 10.1093/rheumatology/kex291] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 5.8] [Reference Citation Analysis]
26 Durkin SM, Christidis D. Recurrent pneumococcal bacteraemia in a patient with systemic lupus erythematosus. Clinical Infection in Practice 2021;9:100062. [DOI: 10.1016/j.clinpr.2020.100062] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Lever E, Alves MR, Isenberg DA. Towards Precision Medicine in Systemic Lupus Erythematosus. Pharmgenomics Pers Med 2020;13:39-49. [PMID: 32099443 DOI: 10.2147/PGPM.S205079] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
28 Ugarte A, Danza A, Ruiz-irastorza G. Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions. Current Opinion in Rheumatology 2018;30:482-9. [DOI: 10.1097/bor.0000000000000527] [Cited by in Crossref: 30] [Cited by in F6Publishing: 7] [Article Influence: 7.5] [Reference Citation Analysis]
29 Derwand R, Scholz M, Zelenko V. COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study. Int J Antimicrob Agents 2020;56:106214. [PMID: 33122096 DOI: 10.1016/j.ijantimicag.2020.106214] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 16.5] [Reference Citation Analysis]
30 Richard-eaglin A, Smallheer BA. Immunosuppressive/Autoimmune Disorders. Nursing Clinics of North America 2018;53:319-34. [DOI: 10.1016/j.cnur.2018.04.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
31 Jones A, Muller P, Dore CJ, Ikeji F, Caverly E, Chowdhury K, Isenberg DA, Gordon C, Ehrenstein MR. Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial. BMJ Open 2019;9:e032569. [PMID: 31848169 DOI: 10.1136/bmjopen-2019-032569] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
32 Misra DP, Sharma A, Agarwal V. Rheumatology science and practice in India. Rheumatol Int 2018;38:1587-600. [PMID: 30022301 DOI: 10.1007/s00296-018-4111-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
33 Garnier C, Ribes D, Chauveau D, Huart A, Pugnet G, Adoue D, Prevot G, Alric L, Delobel P, Derumeaux H, Mengelle C, Sailler L, Moulis G. Zoster after Cyclophosphamide for Systemic Lupus Erythematosus or Vasculitis: Incidence, Risk Factors, and Effect of Antiviral Prophylaxis. J Rheumatol 2018;45:1541-8. [DOI: 10.3899/jrheum.180310] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
34 Martín-Iglesias D, Artaraz J, Fonollosa A, Ugarte A, Arteagabeitia A, Ruiz-Irastorza G. Evolution of retinal changes measured by optical coherence tomography in the assessment of hydroxychloroquine ocular safety in patients with systemic lupus erythematosus. Lupus 2019;28:555-9. [PMID: 30755141 DOI: 10.1177/0961203319829826] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
35 Samnaliev M, Barut V, Weir S, Langham J, Langham S, Wang X, Desta B, Hammond E. Health-care utilization and costs in adults with systemic lupus erythematosus in the United Kingdom: a real-world observational retrospective cohort analysis. Rheumatol Adv Pract 2021;5:rkab071. [PMID: 34622127 DOI: 10.1093/rap/rkab071] [Reference Citation Analysis]
36 Mohamed A, Chen Y, Wu H, Liao J, Cheng B, Lu Q. Therapeutic advances in the treatment of SLE. Int Immunopharmacol 2019;72:218-23. [PMID: 31002998 DOI: 10.1016/j.intimp.2019.03.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
37 Margherita Z, Enrico F, Marta LM, Roberto D, Micaela F, Mariele G, Maddalena L, Francesca S, Luca I, Andrea D. Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis. Rheumatology (Oxford) 2021:keab373. [PMID: 33909900 DOI: 10.1093/rheumatology/keab373] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Sayadi L, Faezi ST, Hasanpour M, Alahmadi SJ. The Relationship of Lifestyle with Disease Activity among Patients with Systemic Lupus Erythematosus: A Descriptive-Correlational Study. Mediterr J Rheumatol 2021;32:124-33. [PMID: 34447908 DOI: 10.31138/mjr.32.2.124] [Reference Citation Analysis]
39 Aringer M, Leuchten N, Dörner T. Biologika und „small molecules“ beim systemischen Lupus erythematodes. Z Rheumatol 2020;79:232-40. [DOI: 10.1007/s00393-020-00767-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
40 Htut E, Hall F. Vaccination in SLE patients. Lupus 2018;27:36-9. [DOI: 10.1177/0961203318801697] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
41 Dall'Era M, Bruce IN, Gordon C, Manzi S, McCaffrey J, Lipsky PE. Current challenges in the development of new treatments for lupus. Ann Rheum Dis 2019;78:729-35. [PMID: 30636212 DOI: 10.1136/annrheumdis-2018-214530] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
42 Wiles K, Chappell L, Clark K, Elman L, Hall M, Lightstone L, Mohamed G, Mukherjee D, Nelson-Piercy C, Webster P, Whybrow R, Bramham K. Clinical practice guideline on pregnancy and renal disease. BMC Nephrol. 2019;20:401. [PMID: 31672135 DOI: 10.1186/s12882-019-1560-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
43 Greenan-Barrett J, Doolan G, Shah D, Virdee S, Robinson GA, Choida V, Gak N, de Gruijter N, Rosser E, Al-Obaidi M, Leandro M, Zandi MS, Pepper RJ, Salama A, Jury EC, Ciurtin C. Biomarkers Associated with Organ-Specific Involvement in Juvenile Systemic Lupus Erythematosus. Int J Mol Sci 2021;22:7619. [PMID: 34299237 DOI: 10.3390/ijms22147619] [Reference Citation Analysis]
44 Tanaka Y, Nakayamada S, Yamaoka K, Ohmura K, Yasuda S. Rituximab in the Real-World Treatment of Lupus Nephritis: A Retrospective Cohort Study in Japan. Mod Rheumatol 2022:roac007. [PMID: 35165714 DOI: 10.1093/mr/roac007] [Reference Citation Analysis]
45 Giles I, Allen A, Crossley A, Flint J, Frishman M, Gayed M, Kamashta M, Moore L, Panchal S, Piper M, Reid C, Saxby K, Schreiber K, Senvar N, Tosounidou S, van de Venne M, Warburton L, Wiliams D, Yee CS, Gordon C. Prescribing anti-rheumatic drugs in pregnancy and breastfeeding-the British Society for Rheumatology guideline scope. Rheumatology (Oxford) 2021;60:3565-9. [PMID: 33848327 DOI: 10.1093/rheumatology/keab334] [Reference Citation Analysis]
46 Makarov V, Riabova O, Ekins S, Pluzhnikov N, Chepur S. The past, present and future of RNA respiratory viruses: influenza and coronaviruses. Pathog Dis 2020;78:ftaa046. [PMID: 32860686 DOI: 10.1093/femspd/ftaa046] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
47 Wijetilleka S, Jayne D, Mukhtyar C, Karim MY. Iatrogenic antibody deficiency from B-cell targeted therapies in autoimmune rheumatic diseases. Lupus Sci Med 2019;6:e000337. [PMID: 31413852 DOI: 10.1136/lupus-2019-000337] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Ashuntantang GE, Garovic VD, Heilberg IP, Lightstone L. Kidneys and women's health: key challenges and considerations. Nat Rev Nephrol 2018;14:203-10. [PMID: 29380816 DOI: 10.1038/nrneph.2017.188] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
49 Magro R. Biological therapies and their clinical impact in the treatment of systemic lupus erythematosus. Ther Adv Musculoskelet Dis 2019;11:1759720X19874309. [PMID: 31565077 DOI: 10.1177/1759720X19874309] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
50 Xiao N, He X, Niu H, Yu H, Cui N, Li H, Yan L, Shao Z, Xing L, Wang H. Increased Circulating CD4+CXCR5+ Cells and IgG4 Levels in Patients with Myelodysplastic Syndrome with Autoimmune Diseases. J Immunol Res 2021;2021:4302515. [PMID: 34631897 DOI: 10.1155/2021/4302515] [Reference Citation Analysis]
51 Robson JC, Shepherd M, Harper L, Ndosi M, Austin K, Flurey C, Logan S, Dures E. Psychological and self-management support for people with vasculitis or connective tissue diseases: UK health professionals' perspectives. Rheumatol Adv Pract 2020;4:rkaa016. [PMID: 32968704 DOI: 10.1093/rap/rkaa016] [Reference Citation Analysis]
52 Goehner Schweizer K, Maurer B. [New and Established Therapeutic Options for the Treatment of Systemic Lupus Erythematosus]. Praxis (Bern 1994) 2020;109:341-5. [PMID: 32233759 DOI: 10.1024/1661-8157/a003443] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
53 Oku K, Atsumi T. Systemic lupus erythematosus: nothing stale her infinite variety. Mod Rheumatol 2018;28:758-65. [PMID: 29947275 DOI: 10.1080/14397595.2018.1494239] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
54 Casciaro M, Di Salvo E, Brizzi T, Rodolico C, Gangemi S. Involvement of miR-126 in autoimmune disorders. Clin Mol Allergy 2018;16:11. [PMID: 29743819 DOI: 10.1186/s12948-018-0089-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
55 Martinez GP, Zabaleta ME, Di Giulio C, Charris JE, Mijares MR. The Role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases. CPD 2020;26:4467-85. [DOI: 10.2174/1381612826666200707132920] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
56 Tian J, Zhou H, Fang D, Yi P, Cao P, Liu J, Xiong F, Zhang B, Liu Y, Tsokos GC, Lu Q. The global burden of heterogeneity of lupus erythematosus interventional trials. J Autoimmun 2022;128:102798. [PMID: 35182896 DOI: 10.1016/j.jaut.2022.102798] [Reference Citation Analysis]
57 Ji LN, Wu S, Fu DQ, Fang SJ, Xie GQ, Fan YS, Bao J. Jieduquyuziyin Prescription alleviates hepatic gluconeogenesis via PI3K/Akt/PGC-1α pathway in glucocorticoid-induced MRL/lpr mice. J Ethnopharmacol 2022;284:114815. [PMID: 34763039 DOI: 10.1016/j.jep.2021.114815] [Reference Citation Analysis]
58 [DOI: 10.1101/2020.03.22.20040758] [Cited by in Crossref: 291] [Cited by in F6Publishing: 55] [Reference Citation Analysis]
59 Mebrahtu TF, Morgan AW, West RM, Stewart PM, Pujades-Rodriguez M. Oral glucocorticoids and incidence of hypertension in people with chronic inflammatory diseases: a population-based cohort study. CMAJ 2020;192:E295-301. [PMID: 32392512 DOI: 10.1503/cmaj.191012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
60 Gatto M, Zen M, Iaccarino L, Doria A. New therapeutic strategies in systemic lupus erythematosus management. Nat Rev Rheumatol 2019;15:30-48. [DOI: 10.1038/s41584-018-0133-2] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 10.0] [Reference Citation Analysis]
61 Ruiz-irastorza G, Ugarte A, Ruiz-arruza I, Khamashta M. Seventy years after Hench’s Nobel prize: revisiting the use of glucocorticoids in systemic lupus erythematosus. Lupus 2020;29:1155-67. [DOI: 10.1177/0961203320930099] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
62 Aduriz-lorenzo PM, Aduriz-llaneza P, Araiz-iribarren J, Khamashta MA. Current opinion on hydroxychloroquine-related retinal toxicity screening: where do we stand now? Lupus 2020;29:671-5. [DOI: 10.1177/0961203320919499] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
63 Kernder A, Richter JG, Fischer-Betz R, Winkler-Rohlfing B, Brinks R, Schneider M, Chehab G. Quality of care predicts outcome in systemic lupus erythematosus: a cross-sectional analysis of a German long-term study (LuLa cohort). Lupus 2020;29:136-43. [PMID: 31992161 DOI: 10.1177/0961203319896626] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
64 Fischer-Betz R, Schneider M. [Deescalation and glucocorticoid-free treatment in SLE]. Z Rheumatol 2021;80:332-8. [PMID: 33721043 DOI: 10.1007/s00393-021-00981-w] [Reference Citation Analysis]
65 Mucke J, Fischer-betz R, Schneider M. State of the Art: systemischer Lupus erythematodes. Z Rheumatol 2019;78:500-10. [DOI: 10.1007/s00393-019-0633-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
66 Murimi-Worstell IB, Lin DH, Kan H, Tierce J, Wang X, Nab H, Desta B, Alexander GC, Hammond ER. Healthcare Utilization and Costs of Systemic Lupus Erythematosus by Disease Severity in the United States. J Rheumatol 2021;48:385-93. [PMID: 32611669 DOI: 10.3899/jrheum.191187] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
67 Jiménez-Zarazúa O, Vélez-Ramírez LN, Ramírez-Casillas CA, Mondragón JD. Pulmonary thromboembolism and alveolar hemorrhage as initial manifestations of systemic lupus erythematosus. Lupus 2022;:9612033211066481. [PMID: 35042383 DOI: 10.1177/09612033211066481] [Reference Citation Analysis]
68 Lee AYS, Brown DA, McDonald D, Lin MW. Longitudinal Tracking of Extractable Nuclear Antigen (ENA) Antibodies in a Quaternary Hospital Laboratory Cohort Reveals Dynamic Antibody Profiles. J Appl Lab Med 2022;7:26-35. [PMID: 34996068 DOI: 10.1093/jalm/jfab104] [Reference Citation Analysis]
69 Goulden B, Isenberg D. Anti-IFNαR Mabs for the treatment of systemic lupus erythematosus. Expert Opin Biol Ther 2021;21:519-28. [PMID: 33085537 DOI: 10.1080/14712598.2021.1841164] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
70 Roberts EJ, Melchionda V, Saldanha G, Shaffu S, Royle J, Harman KE. Toxic epidermal necrolysis-like lupus. Clin Exp Dermatol 2021. [PMID: 33760256 DOI: 10.1111/ced.14648] [Reference Citation Analysis]
71 Magro R, Borg AA. Characterisation of Patients with Systemic Lupus Erythematosus in Malta: A Population Based Cohort Cross-Sectional Study. Biomed Res Int 2018;2018:2385386. [PMID: 30364091 DOI: 10.1155/2018/2385386] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
72 Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, Pham HP, Schneiderman J, Witt V, Wu Y, Zantek ND, Dunbar NM, Schwartz GEJ. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019;34:171-354. [PMID: 31180581 DOI: 10.1002/jca.21705] [Cited by in Crossref: 314] [Cited by in F6Publishing: 277] [Article Influence: 104.7] [Reference Citation Analysis]
73 Mason A, Anver H, Lwin M, Holroyd C, Faust SN, Edwards CJ. Lupus, vaccinations and COVID-19: What we know now. Lupus 2021;:9612033211024355. [PMID: 34134555 DOI: 10.1177/09612033211024355] [Reference Citation Analysis]
74 Jesus D, Larosa M, Henriques C, Matos A, Zen M, Tomé P, Alves V, Costa N, Le Guern V, Iaccarino L, Costedoat-Chalumeau N, Doria A, Inês LS. Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity. Ann Rheum Dis 2021:annrheumdis-2021-220363. [PMID: 34407927 DOI: 10.1136/annrheumdis-2021-220363] [Reference Citation Analysis]
75 Elera-fitzcarrald C, Fuentes A, González LA, Burgos PI, Alarcón GS, Ugarte-gil MF. Factors affecting quality of life in patients with systemic lupus erythematosus: important considerations and potential interventions. Expert Review of Clinical Immunology 2018;14:915-31. [DOI: 10.1080/1744666x.2018.1529566] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 5.3] [Reference Citation Analysis]
76 Tanaka Y, Tummala R. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials. Mod Rheumatol 2021;31:1-12. [PMID: 32814461 DOI: 10.1080/14397595.2020.1812201] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
77 Gavan S, Bruce I, Payne K. Generating evidence to inform health technology assessment of treatments for SLE: a systematic review of decision-analytic model-based economic evaluations. Lupus Sci Med 2020;7:e000350. [PMID: 32723809 DOI: 10.1136/lupus-2019-000350] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
78 Zen M, Saccon F, Gatto M, Montesso G, Larosa M, Benvenuti F, Iaccarino L, Doria A. Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission. Rheumatology 2020;59:1591-8. [DOI: 10.1093/rheumatology/kez422] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
79 Tamirou F, Arnaud L, Talarico R, Scirè CA, Alexander T, Amoura Z, Avcin T, Bortoluzzi A, Cervera R, Conti F, Cornet A, Devilliers H, Doria A, Frassi M, Fredi M, Govoni M, Houssiau F, Lladò A, Macieira C, Martin T, Massaro L, Moraes-Fontes MF, Pamfil C, Paolino S, Tani C, Tas SW, Tektonidou M, Tincani A, Van Vollenhoven RF, Bombardieri S, Burmester G, Eurico FJ, Galetti I, Hachulla E, Mueller-Ladner U, Schneider M, Smith V, Cutolo M, Mosca M, Costedoat-Chalumeau N. Systemic lupus erythematosus: state of the art on clinical practice guidelines. RMD Open 2018;4:e000793. [PMID: 30564454 DOI: 10.1136/rmdopen-2018-000793] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
80 Han X, Li C, Zhang S, Hou X, Chen Z, Zhang J, Zhang Y, Sun J, Wang Y. Why thromboembolism occurs in some patients with thrombocytopenia and treatment strategies. Thromb Res 2020;196:500-9. [PMID: 33091704 DOI: 10.1016/j.thromres.2020.10.005] [Reference Citation Analysis]
81 Cassia MA, Alberici F, Jones RB, Smith RM, Casazza G, Urban ML, Emmi G, Moroni G, Sinico RA, Messa P, Hall F, Vaglio A, Gallieni M, Jayne DR. Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 Patients. Arthritis Rheumatol 2019;71:1670-80. [PMID: 31102498 DOI: 10.1002/art.40932] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
82 Furie R, Morand EF, Askanase AD, Vital EM, Merrill JT, Kalyani RN, Abreu G, Pineda L, Tummala R. Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus. Lupus 2021;30:1254-63. [PMID: 33977796 DOI: 10.1177/09612033211014267] [Reference Citation Analysis]
83 Yates M. Commonly used medication for Lupus. Lupus 2018;27:8-10. [PMID: 30452320 DOI: 10.1177/0961203318801670] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
84 Gordon C, Amissah-arthur M, Gayed M, Brown S, Bruce IN, D’cruz D, Empson B, Griffiths B, Jayne D, Khamashta M, Lightstone L, Norton P, Norton Y, Schreiber K, Isenberg D; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Comment on: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: reply. Rheumatology 2018;57:1502-3. [DOI: 10.1093/rheumatology/key170] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
85 Guo X, Yang X, Li Q, Shen X, Zhong H, Yang Y. The Microbiota in Systemic Lupus Erythematosus: An Update on the Potential Function of Probiotics. Front Pharmacol 2021;12:759095. [PMID: 34887760 DOI: 10.3389/fphar.2021.759095] [Reference Citation Analysis]
86 Petta I, Peene I, Elewaut D, Vereecke L, De Bosscher K. Risks and benefits of corticosteroids in arthritic diseases in the clinic. Biochem Pharmacol 2019;165:112-25. [PMID: 30978323 DOI: 10.1016/j.bcp.2019.04.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
87 Figueroa-parra G, Gamboa-alonso CM, De-leon-ibarra AL, Galarza-delgado DA. 2019 update of the EULAR recommendations for the management of SLE: don’t forget chloroquine. Ann Rheum Dis 2020;79:e114-e114. [DOI: 10.1136/annrheumdis-2019-215716] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
88 Dima A, Jurcut C, Baicus C. The impact of anti-U1-RNP positivity: systemic lupus erythematosus versus mixed connective tissue disease. Rheumatol Int 2018;38:1169-78. [DOI: 10.1007/s00296-018-4059-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
89 Pearce FA, Rutter M, Sandhu R, Batten RL, Garner R, Little J, Narayan N, Sharp CA, Bruce IN, Erb N, Griffiths B, Guest H, Macphie E, Packham J, Hiley C, Obrenovic K, Rivett A, Gordon C, Lanyon PC. BSR guideline on the management of adults with systemic lupus erythematosus (SLE) 2018: baseline multi-centre audit in the UK. Rheumatology (Oxford) 2021;60:1480-90. [PMID: 33291150 DOI: 10.1093/rheumatology/keaa759] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
90 Tao CY, Shang J, Chen T, Yu D, Jiang YM, Liu D, Cheng GY, Xiao J, Zhao ZZ. Impact of antimalarial (AM) on serum lipids in systemic lupus erythematosus (SLE) patients: A systematic review and meta-analysis. Medicine (Baltimore) 2019;98:e15030. [PMID: 30946340 DOI: 10.1097/MD.0000000000015030] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 3.7] [Reference Citation Analysis]
91 Oliveira M, Palacios-Fernandez S, Cervera R, Espinosa G. Clinical practice guidelines and recommendations for the management of patients with systemic lupus erythematosus: a critical comparison. Rheumatology (Oxford) 2020;59:3690-9. [PMID: 32375178 DOI: 10.1093/rheumatology/keaa142] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
92 Alarcón GS, Cardiel MH, Izcovich A, Scheinberg M, Pons-Estel BA. A Critical Analysis of the First Latin American Clinical Practice Guidelines for the Treatment of Systemic Lupus Erythematosus. J Clin Rheumatol 2022;28:e312-6. [PMID: 31895089 DOI: 10.1097/RHU.0000000000001265] [Reference Citation Analysis]
93 Trindade VC, Carneiro-Sampaio M, Bonfa E, Silva CA. An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus. Paediatr Drugs 2021;23:331-47. [PMID: 34244988 DOI: 10.1007/s40272-021-00457-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
94 Xiong J, Ren Y, Li H, Fu B, Wu R. First case of pleural amyloidosis in systemic erythematosus: report and literature review. Z Rheumatol 2018;77:841-3. [PMID: 30191392 DOI: 10.1007/s00393-018-0532-4] [Reference Citation Analysis]
95 Hammond ER, Desta B, Near AM, Wang X, Jiang M. Frequency, severity and costs of flares increase with disease severity in newly diagnosed systemic lupus erythematosus: a real-world cohort study, United States, 2004-2015. Lupus Sci Med 2021;8:e000504. [PMID: 34556546 DOI: 10.1136/lupus-2021-000504] [Reference Citation Analysis]
96 Ruiz-Irastorza G, Bertsias G. Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. Rheumatology (Oxford) 2020;59:v69-81. [PMID: 33280011 DOI: 10.1093/rheumatology/keaa403] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
97 Ntatsaki E, Vassiliou VS, Velo-Garcia A, Salama AD, Isenberg DA. Renal transplantation for lupus nephritis: non-adherence and graft survival. Lupus 2019;28:651-7. [PMID: 30982400 DOI: 10.1177/0961203319842641] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
98 Jung UH, Kwak SG, Choe JY, Lee SS, Kim SK. The Effect of Mycophenolate Mofetil on Non-Renal Manifestations in Systemic Lupus Erythematosus: Results from Korean Lupus Network Registry. J Korean Med Sci 2019;34:e185. [PMID: 31293110 DOI: 10.3346/jkms.2019.34.e185] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
99 Smith EMD, Lythgoe H, Midgley A, Beresford MW, Hedrich CM. Juvenile-onset systemic lupus erythematosus: Update on clinical presentation, pathophysiology and treatment options. Clin Immunol 2019;209:108274. [PMID: 31678365 DOI: 10.1016/j.clim.2019.108274] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
100 Nasonov EL, Beketova TV, Ananyeva LP, Vasilyev VI, Solovyev SK, Avdeeva AS. PROSPECTS FOR ANTI-B-CELL THERAPY IN IMMUNO-INFLAMMATORY RHEUMATIC DISEASES. Naučno-praktičeskaâ revmatologiâ 2019;57:1-40. [DOI: 10.14412/1995-4484-2019-3-40] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
101 Edwards CJ, Bellinvia S. Biosimilars. Lupus 2020;29:525-32. [PMID: 32188301 DOI: 10.1177/0961203320910797] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
102 Landry C, Burger D. Hypertension and vascular alterations in lupus autoimmunity. J Hypertens 2020;38:1257-8. [PMID: 32502094 DOI: 10.1097/HJH.0000000000002405] [Reference Citation Analysis]
103 Geh D, Gordon C. Epratuzumab for the treatment of systemic lupus erythematosus. Expert Rev Clin Immunol 2018;14:245-58. [PMID: 29542345 DOI: 10.1080/1744666X.2018.1450141] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
104 Dima A, Jurcut C, Chasset F, Felten R, Arnaud L. Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. Therapeutic Advances in Musculoskeletal 2022;14:1759720X2110730. [DOI: 10.1177/1759720x211073001] [Reference Citation Analysis]
105 Gomez A, Qiu V, Cederlund A, Borg A, Lindblom J, Emamikia S, Enman Y, Lampa J, Parodis I. Adverse Health-Related Quality of Life Outcome Despite Adequate Clinical Response to Treatment in Systemic Lupus Erythematosus. Front Med (Lausanne) 2021;8:651249. [PMID: 33937290 DOI: 10.3389/fmed.2021.651249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Nakayamada S, Tanaka Y. Pathological relevance and treatment perspective of JAK targeting in systemic lupus erythematosus. Expert Rev Clin Immunol 2022. [PMID: 35138987 DOI: 10.1080/1744666X.2022.2040988] [Reference Citation Analysis]
107 Tian J, Luo Y, Wu H, Long H, Zhao M, Lu Q. Risk of adverse events from different drugs for SLE: a systematic review and network meta-analysis. Lupus Sci Med 2018;5:e000253. [PMID: 29644081 DOI: 10.1136/lupus-2017-000253] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
108 Gamea GA, Elmehy DA, Salama AM, Soliman NA, Afifi OK, Elkaliny HH, Abo El Gheit RE, El-Ebiary AA, Tahoon DM, Elkholy RA, Shoeib SM, Eleryan MA, Younis SS. Direct and indirect antiparasitic effects of chloroquine against the virulent RH strain of Toxoplasma gondii: An experimental study. Acta Trop 2022;:106508. [PMID: 35568067 DOI: 10.1016/j.actatropica.2022.106508] [Reference Citation Analysis]
109 Ruiz-irastorza G, Ruiz-estevez B, Lazaro E, Ruiz-arruza I, Duffau P, Martin-cascon M, Richez C, Ugarte A, Blanco P. Prolonged remission in SLE is possible by using reduced doses of prednisone: An observational study from the Lupus-Cruces and Lupus-Bordeaux inception cohorts. Autoimmunity Reviews 2019;18:102359. [DOI: 10.1016/j.autrev.2019.102359] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
110 Fasano S, Margiotta DPE, Pierro L, Navarini L, Riccardi A, Afeltra A, Valentini G. Prolonged remission is associated with a reduced risk of cardiovascular disease in patients with systemic lupus erythematosus: a GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study. Clin Rheumatol 2019;38:457-63. [PMID: 30194649 DOI: 10.1007/s10067-018-4286-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
111 Soriano-Maldonado A, Morillas-de-Laguno P, Sabio JM, Gavilán-Carrera B, Rosales-Castillo A, Montalbán-Méndez C, Sáez-Urán LM, Callejas-Rubio JL, Vargas-Hitos JA. Effects of 12-week Aerobic Exercise on Arterial Stiffness, Inflammation, and Cardiorespiratory Fitness in Women with Systemic LUPUS Erythematosus: Non-Randomized Controlled Trial. J Clin Med 2018;7:E477. [PMID: 30477218 DOI: 10.3390/jcm7120477] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
112 Khuroo MS. Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal. Int J Antimicrob Agents 2020;56:106101. [PMID: 32687949 DOI: 10.1016/j.ijantimicag.2020.106101] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 17.5] [Reference Citation Analysis]
113 Ubhi M, Dubey S, Gordon C, Adizie T, Sheeran T, Allen K, Jordan R, Sadhra S, Adams J, Daji R, Reynolds JA, Kumar K. Understanding the impact of systemic lupus erythematosus on work amongst South Asian people in the UK: An explorative qualitative study. Lupus 2021;30:1492-501. [PMID: 34092136 DOI: 10.1177/09612033211022816] [Reference Citation Analysis]
114 Ahn SS, Yoo J, Jung SM, Song JJ, Park YB, Lee SW. Comparison of clinical features and outcomes between patients with early and delayed lupus nephritis. BMC Nephrol 2020;21:258. [PMID: 32635898 DOI: 10.1186/s12882-020-01915-5] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]